News
![Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71305/Aktiencheck_Vidac_120723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenRMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5b3f64bfef07fa8bd92ce1bf962296d13aace5ef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck_Vidac_120723.001.png?locale=us)
Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Erstkl. Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. 208% Biotech Hot Stock nach 31.205% mit Amgen
12.07.23 08:02
London (www.aktiencheck.de, Anzeige)
![Biotech Hot Stock erzielt Durchbruch im Kampf gegen Hautkrebs. Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 208% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Bi: https://www.irw-press.at/prcom/images/messages/2023/71290/Aktiencheck110723_01.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNDlKYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--787d8ebddd6748c6adbc693ec025f1daf5be4277/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck110723_01.001.png?locale=us)
Biotech Hot Stock erzielt Durchbruch im Kampf gegen Hautkrebs. Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 208% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Bi
Biotech Hot Stock erzielt Durchbruch im Kampf gegen Hautkrebs - Massives Kaufsignal. 208% Biotech Aktientip nach 134452%
11.07.23
London (www.aktiencheck.de, Anzeige)
![Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi: https://www.marketbeat.com/logos/articles/med_20230707134150_biogen-shares-fall-after-fda-approval-of-alzheimer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmRJYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1dbde6a5e8e414c90db91c96080cd62ebf404107/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230707134150_biogen-shares-fall-after-fda-approval-of-alzheimer.jpg?locale=us)
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
Stocks often react differently from the way you think they might. That happened on July 7 as shares of Biogen Inc. (NASDAQ: BIIB) swooned 2.88% in heavy trading volume following news of full
![Hautkrebs bald besiegt? Round Table mit Europas Top-Forschern. Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 210% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Bi: https://www.irw-press.at/prcom/images/messages/2023/71270/AC-100723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzlJYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a7bf8398bb6a9cb8511ab94d21b47a578fbf7566/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-100723.001.png?locale=us)
Hautkrebs bald besiegt? Round Table mit Europas Top-Forschern. Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 210% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Bi
Hautkrebs bald besiegt? Round Table mit Europas Top-Forschern. 210% Biotech Aktientip nach 15.973% mit BioNTech ($BNTX)
10.07.23 08:11
London (www.aktiencheck.de, Anzeige)
![Pfizer Just Invested $25 million In This Biotech: https://www.marketbeat.com/logos/articles/med_20230707085820_pfizer-just-invested-25-million-in-this-biotech.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeGxIYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--262be44f890d0485b2cae73bedbf5cf6c7ecbcc9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230707085820_pfizer-just-invested-25-million-in-this-biotech.jpg?locale=us)
Pfizer Just Invested $25 million In This Biotech
Shares of Caribou Biosciences (NASDAQ: CRBU) were up 45% yesterday after Pfizer (NYSE: PFE) made a $25 million equity investment. On Thursday, the company said Pfizer bought almost 4.7 million
![Hautkrebs bald besiegt? Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 212% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 212% mit Biotech Ak: https://www.irw-press.at/prcom/images/messages/2023/71257/AC-070723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNHBHYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0d3a54f1f977c1100e4201991eea788b0e347107/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-070723.001.png?locale=us)
Hautkrebs bald besiegt? Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 212% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 212% mit Biotech Ak
Hautkrebs bald besiegt? Erstkl. Studienergebnisse. Massives Kaufsignal. 212% Biotech Hot Stock nach 134.452% mit Biogen
07.07.23 08:02
London (www.aktiencheck.de, Anzeige)
![Eilt: Durchbruch im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 217% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vida: https://www.irw-press.at/prcom/images/messages/2023/71245/AC-060723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeE5GYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--56515343a35b8591b959e4c64524c8811c3d4a26/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-060723.001.png?locale=us)
Eilt: Durchbruch im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 217% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vida
Eilt: Durchbruch im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 217% Biotech Aktientip nach 15.973% mit BioNTech
06.07.23 08:02
London (www.aktiencheck.de , Anzeige)
![Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac : https://www.irw-press.at/prcom/images/messages/2023/71224/AC_VidacPharma_050723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzVEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e681713d74d225c9ff5e1cb9ac83ef3ff82c2797/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC_VidacPharma_050723.001.png?locale=us)
Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac
Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 134.452% mit Biogen
05.07.23 08:17
London (www.aktiencheck.de, Anzeige)
![Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71203/Acresearch040723_01.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1pEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9cf6ff849545ee031a7c43df64ea5ff8aadf9f90/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Acresearch040723_01.001.png?locale=us)
Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 31.205% mit Amgen ($AMGN)
04.07.23
London (www.aktiencheck.de, Anzeige)
![Krebs bald besiegt? Sensationelle Studienergebnisse. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 224% mit Biotech Aktientip Vidac Pharma : https://www.irw-press.at/prcom/images/messages/2023/71194/AC-030723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHhDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--411a50a5bdc2c7746cdb91e78cd09754c59906ac/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-030723.001.png?locale=us)
Krebs bald besiegt? Sensationelle Studienergebnisse. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 224% mit Biotech Aktientip Vidac Pharma
Krebs bald besiegt? Sensationelle Studienergebnisse. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX)
03.07.23 08:17
London (www.aktiencheck.de , Anzeige)
![Bullish or Bearish? Vetting Animal Health Care Stocks: https://www.marketbeat.com/logos/articles/med_20230616064027_bullish-or-bearish-vetting-animal-health-care-stoc.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNTh5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--60213dddc89f9c73c1d508eef5a627d55359838e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230616064027_bullish-or-bearish-vetting-animal-health-care-stoc.jpg?locale=us)
Bullish or Bearish? Vetting Animal Health Care Stocks
Dogs and cats were among the biggest beneficiaries of the pandemic thanks to more attention from housebound pet owners. Pet adoption trends also skyrocketed.
As Fido and Fluffy were spoiled more
![Is the Biotech Industry (IBB) Poised For A Major Breakout?: https://www.marketbeat.com/logos/articles/med_20230612064640_is-the-biotech-industry-ibb-poised-for-a-major-bre.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNThzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b2019bb6eec0d8ebc1d9c14bfd208c60f1847e8f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230612064640_is-the-biotech-industry-ibb-poised-for-a-major-bre.jpg?locale=us)
Is the Biotech Industry (IBB) Poised For A Major Breakout?
The iShares Biotechnology ETF (NASDAQ: IBB) has recently shown signs of potential consolidation leading to a breakout. Such price action and development should prompt investors to notice possible
![Tax Software Specialist Vertex In Buy Zone After Base Breakout: https://www.marketbeat.com/logos/articles/med_20230609080552_tax-software-specialist-vertex-in-buy-zone-after-b.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekVyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5d6fcd78862843593e6552c04e65760307d5edc4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230609080552_tax-software-specialist-vertex-in-buy-zone-after-b.jpg?locale=us)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
Tax software may not be the most glamorous business; as of today, no company in that industry has launched a virtual reality headset. However, if you’re scouting for a company with solid
![Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application: https://www.marketbeat.com/logos/articles/med_20230530101326_chart-iova.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGNlYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5fd6ded371298788dd07c02b2ba5ece13592b28b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230530101326_chart-iova.jpg?locale=us)
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Administration (FDA). The company submitted, and
![Pfizer Has the Prescription for Higher Share Prices: https://www.marketbeat.com/logos/articles/med_20230524125944_pfizer-has-the-prescription-for-higher-share-price.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXdhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0c784121f528beec1f7021789f460466cc29d071/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230524125944_pfizer-has-the-prescription-for-higher-share-price.jpg?locale=us)
Pfizer Has the Prescription for Higher Share Prices
Pfizer Inc. (NYSE: PFE) released the results of a peer review study that sent shares up more than 5%. The study evaluated the company’s GLP-1 receptor agonist, danuglipron. The compound aimed to
![Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine: https://www.irw-press.at/prcom/images/messages/2023/70633/Accesswire-Neurimmune_220523.001.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1lWYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4eed58c15c2cef3ad074a955184a356e9489f7b5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Accesswire-Neurimmune_220523.001.jpeg?locale=us)
Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine
Results also presented during late-breaking session at ESC Heart Failure congress 2023
ZURICH, SWITZERLAND / ACCESSWIRE / May 20, 2023 / Neurimmune announced today that primary results of
![Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?: https://www.marketbeat.com/logos/articles/med_20230518141428_is-pfizers-seagen-deal-in-jeopardy-amid-antitrust.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNk1UYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--828975049b596f383745f5396fd915be2235140a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518141428_is-pfizers-seagen-deal-in-jeopardy-amid-antitrust.jpg?locale=us)
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
Pfizer Inc. (NYSE: PFE) continued its downward trajectory on May 17, following news that the Federal Trade Commission is seeking to block Amgen Inc.’s (NASDAQ: AMGN) planned acquisition of Horizon
![Zoetis Declares New Dividend, Hinting At Undervaluation: https://www.marketbeat.com/logos/articles/med_20230518102050_zoetis-declares-new-dividend-hinting-at-undervalua.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOEVTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3c586cb6fc0711a2c928535d3df9a038565bda71/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518102050_zoetis-declares-new-dividend-hinting-at-undervalua.jpg?locale=us)
Zoetis Declares New Dividend, Hinting At Undervaluation
Zoetis (NYSE: ZTS) shareholders may have a new reference point to be excited about, even after witnessing some favorable developments through the company's first quarter 2023 announcements. Even
![Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings: https://www.marketbeat.com/logos/articles/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGtTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fe1fa8a76cffa1e1d1a7a5af6f98fc7532bc5f23/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg?locale=us)
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), maker of Cystic fibrosis drugs, rallied to a record high on May 2 after a better-than-expected first-quarter earnings report.
Net income of $3.05 a
![The Turnaround for Weight Watchers is Taking Shape: https://www.marketbeat.com/logos/articles/med_20230514180546_charty-ww.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGdPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff351f66c02189ec9ff23c0f8c44db4d7d59a6ef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230514180546_charty-ww.jpg?locale=us)
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares collapsed (26%) as Artal Group S.A
![Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales: https://www.marketbeat.com/logos/articles/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2tCYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--26208beaff1e53954dadcf470598a9dc71a7ffae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg?locale=us)
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.
Net income tumbled by 12% to $10.09 a
![High-Yield Pfizer Falls Off The COVID Cliff, And Survives: https://www.marketbeat.com/logos/articles/med_20230502093017_chart-pfe-522023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1Q4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c311c303e106fc0d8d8d3da758dae9bcd621a7f1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230502093017_chart-pfe-522023.png?locale=us)
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is
![Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal: https://www.marketbeat.com/logos/articles/med_20230425102047_chart-viri.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNi84YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e765016dc4874369137a4917d444f93993635bd3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230425102047_chart-viri.jpg?locale=us)
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune
![Why Legend Biotech Stock Is Having Its Best Month Yet: https://www.marketbeat.com/logos/articles/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2I4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e0fb704b76cef35f42fad2a7857b3b605b658608/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg?locale=us)
Why Legend Biotech Stock Is Having Its Best Month Yet
Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.
On April 19th, a
![Weight Watchers Reshapes Itself with a Game-Changer Acquisition: https://www.marketbeat.com/logos/articles/med_20230411112556_chartt-ww.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVBzYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d9fc96dd5bcfbc7ab9a86816e6a4fd4a7aa020a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230411112556_chartt-ww.jpg?locale=us)
Weight Watchers Reshapes Itself with a Game-Changer Acquisition
Weight management food and services provider WW International Inc. (NYSE: WW) stock took a 25% spike as it closed its acquisition of telehealth weight loss platform provider Sequence Inc. WW